IP rules exemption for world's poorest "countries falls short"
This article was originally published in Scrip
Executive Summary
The World Trade Organization has granted the world's poorest countries a five-year stay of execution for applying WTO TRIPS Agreement intellectual property rules to pharmaceuticals. But the WTO's "half-hearted compromise" on a plea from least-developed countries to exempt them altogether is unsatisfactory because the exemption is still time bound, says Médecins Sans Frontières.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.